Mae'n bosibl bod aelodau hefyd yn ymwybodol y bu oedi o ran argaeledd brechlyn pedwarfalent a gynhyrchir gan Sanofi, sef brechlyn a argymhellir ar gyfer oedolion o dan 65 oed sy'n wynebu risg. Mae'r oedi o ran cyhoeddi cyfansoddion y brechlyn ar gyfer y gaeaf hwn wedi rhoi pwysau ychwanegol ar weithgynhyrchwyr i gynhyrchu'r miliynau o frechlynnau sydd eu hangen ar gyfer hemisffer y gogledd erbyn yr adeg arferol. Mae hyn wedi cael mwy o effaith ar y brechlynnau hynny sy'n cymryd mwy o amser i'w cynhyrchu, ac mae hyn wedi arwain at anfon cyflenwadau fesul cam i bractisau.
Members may also be aware that there have been delays in the availability of a quadrivalent vaccine manufactured by Sanofi, recommended for at risk adults under 65 years of age. The delay in announcing the vaccine composition for this winter has put additional pressure on manufacturers to produce the millions of vaccines required for the northern hemisphere by the usual time. The vaccines that take longer to produce have been affected more, and in this case have resulted in staggered deliveries to practices.